Dr. Macy Jin, MD

Director, CRO Services at WuXi Biologics

Speaker

Macy Jin joined WuXi Biologics in April 2023 as a subject matter expert in Biotherapeutic Drug Discovery. Previously, she spent over 20 years at Wyeth/Pfizer, progressing from individual contributor to display platform group leader and project team leader in antibody discovery across oncology, autoimmune, and rare diseases. Macy brings extensive technical expertise, with 10 years in hybridoma and over 10 years in display-based antibody discovery technologies. She led phage panning and screening strategies to isolate Marsticimab (Hympavzi), FDA-approved in 2024 as the first anti-TFPI antibody for Hemophilia.